Andere talen Gland Pharma Limited Bombay S.E.

Aandelen

GLAND

INE068V01023

Beurs gesloten - Bombay S.E. Andere beurzen 12:00:49 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.729 ^INR	-0,55%		-1,86%	-10,11%

08/04	Nicomac Machinery en RP Advisory Services verkopen naar verluidt waarschijnlijk 4,4% belang in Gland Pharma via blokdeals	CI
08/04	Gland Pharma krijgt goedkeuring van de Amerikaanse FDA voor Eribulin Mesylate Injection	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals	08/04
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection	08/04
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial	06/04
Gland Pharma COO, Chief Technical Officer Step Down	25/03
Gland Pharma Limited Announces Change in Management	25/03
Gland Pharma Names New President of Phixen Subsidiary	27/02
Gland Pharma's Consolidated Profit Drops in Fiscal Q3	15/02
Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Indian shares set to open lower as hot US inflation spurs rate worries	14/02
Gland Pharma Gets Establishment Inspection Report from US FDA for Pashamylaram Unit	24/11
32,656,565 Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	18/11
Gland Pharma Gets US FDA's Tentative Approval for Generic Hypotension Drug	15/11
Gland Pharma Limited Receives Tentative Approval for Angiotensin II Injection	15/11
Abbott India's Q2 profit climbs on strong sales	09/11
Gland Pharma Gets US FDA's EIR Report Closing Inspection of Visakhapatnam, India Unit	08/11
Indian shares set to open marginally higher	07/11
India's Gland Pharma misses Q2 profit view on higher expenses	06/11
Gland Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	06/11
Gland Pharma Gets EIR from US FDA After Inspection of Pashamylaram Facility in India	26-09-23
Gland Pharma Appoints CEO for Step-Down Subsidiary	20-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Gland Pharma Limited Bombay S.E.

Aandelen

GLAND

INE068V01023

Andere talen

Filters